Core Viewpoint - Haixi New Drug (02637) has seen a significant stock price increase, rising over 12% at one point and currently trading at 111.6 HKD, which is more than 30% above its IPO price of 86.4 HKD [1] Company Overview - Haixi New Drug is a commercial-stage pharmaceutical company that integrates research and development, production, and sales capabilities [1] - The company has 15 approved generic drug products covering multiple therapeutic areas, including the digestive system, cardiovascular system, endocrine system, and nervous system [1] - Haixi New Drug has established a pipeline of four innovative drugs under development, targeting cancer, ophthalmology, and respiratory diseases [1] Future Plans - The company plans to actively explore collaboration opportunities with multinational corporations (MNCs) to enhance its international clinical research and commercialization capabilities [1]
港股异动 | 海西新药(02637)一度涨超12% 较招股价涨超三成 仿制药、创新药双线布局